TY - JOUR
T1 - Peritoneal Dialysis Guidelines 2019 Part 1 (Position paper of Japanese Society of Dialysis Therapy)
AU - Ito, Yasuhiko
AU - Ryuzaki, Munekazu
AU - Sugiyama, Hitoshi
AU - Tomo, Tadashi
AU - Yamashita, Akihiro C.
AU - Ishikawa, Yuichi
AU - Ueda, Atsushi
AU - Kanazawa, Yoshie
AU - Kanno, Yoshihiko
AU - Itami, Noritomo
AU - Ito, Minoru
AU - Kawanishi, Hideki
AU - Nakayama, Masaaki
AU - Tsuruya, Kazuhiko
AU - Yokoi, Hideki
AU - Fukasawa, Mizuya
AU - Terawaki, Hiroyuki
AU - Nishiyama, Kei
AU - Hataya, Hiroshi
AU - Miura, Kenichiro
AU - Hamada, Riku
AU - Nakakura, Hyogo
AU - Hattori, Motoshi
AU - Yuasa, Hidemichi
AU - Nakamoto, Hidetomo
N1 - Funding Information:
Funding for this study was provided by Japanese Society of Dialysis Therapy.
Funding Information:
HY receives research funding from Daiichi Sankyo Co., Baxter, and Mitsubishi Tanabe Pharma Corp.
Funding Information:
HS receives research funding from Sumitomo Dainippon Pharma Co., Genzyme Corp., and Bayer Yakuhin Ltd.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Approximately 10 years have passed since the Peritoneal Dialysis Guidelines were formulated in 2009. Much evidence has been reported during the succeeding years, which were not taken into consideration in the previous guidelines, e.g., the next peritoneal dialysis PD trial of encapsulating peritoneal sclerosis (EPS) in Japan, the significance of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), the effects of icodextrin solution, new developments in peritoneal pathology, and a new international recommendation on a proposal for exit-site management. It is essential to incorporate these new developments into the new clinical practice guidelines. Meanwhile, the process of creating such guidelines has changed dramatically worldwide and differs from the process of creating what were “clinical practice guides.” For this revision, we not only conducted systematic reviews using global standard methods but also decided to adopt a two-part structure to create a reference tool, which could be used widely by the society’s members attending a variety of patients. Through a working group consensus, it was decided that Part 1 would present conventional descriptions and Part 2 would pose clinical questions (CQs) in a systematic review format. Thus, Part 1 vastly covers PD that would satisfy the requirements of the members of the Japanese Society for Dialysis Therapy (JSDT). This article is the duplicated publication from the Japanese version of the guidelines and has been reproduced with permission from the JSDT.
AB - Approximately 10 years have passed since the Peritoneal Dialysis Guidelines were formulated in 2009. Much evidence has been reported during the succeeding years, which were not taken into consideration in the previous guidelines, e.g., the next peritoneal dialysis PD trial of encapsulating peritoneal sclerosis (EPS) in Japan, the significance of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), the effects of icodextrin solution, new developments in peritoneal pathology, and a new international recommendation on a proposal for exit-site management. It is essential to incorporate these new developments into the new clinical practice guidelines. Meanwhile, the process of creating such guidelines has changed dramatically worldwide and differs from the process of creating what were “clinical practice guides.” For this revision, we not only conducted systematic reviews using global standard methods but also decided to adopt a two-part structure to create a reference tool, which could be used widely by the society’s members attending a variety of patients. Through a working group consensus, it was decided that Part 1 would present conventional descriptions and Part 2 would pose clinical questions (CQs) in a systematic review format. Thus, Part 1 vastly covers PD that would satisfy the requirements of the members of the Japanese Society for Dialysis Therapy (JSDT). This article is the duplicated publication from the Japanese version of the guidelines and has been reproduced with permission from the JSDT.
KW - EPS
KW - Exit site
KW - Nutritional management
KW - Optimal dialysis
KW - Peritoneal dialysis
KW - Peritoneal function
KW - Peritonitis
UR - http://www.scopus.com/inward/record.url?scp=85110769585&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110769585&partnerID=8YFLogxK
U2 - 10.1186/s41100-021-00348-6
DO - 10.1186/s41100-021-00348-6
M3 - Article
AN - SCOPUS:85110769585
VL - 7
JO - Renal Replacement Therapy
JF - Renal Replacement Therapy
SN - 2059-1381
IS - 1
M1 - 40
ER -